A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was: is it safe to stop anticoagulants after successful surgery for atrial fibrillation? Altogether, 177 papers were found using the reported search, of which 14 were selected that represented the best evidence to answer the clinical question. Selection criteria included study relevance, primary outcome, size of study population and length of follow-up. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. The weight of evidence, including over 10,000 patient-years of follow-up, supports the discontinuation of warfarin following atrial fibrillation correction procedures as being safe, with an associated annual thromboembolic stroke rate of 0-3.8% off warfarin, in studies where warfarin was stopped at a mean of 3.6 months (range 0-8 months) after the procedure. However, the confidence of this conclusion suffers from a paucity of high-quality randomized controlled trials in the field, with the main body of evidence coming instead from observational non-randomized studies. The stroke rate also varies with the exact procedure performed; pulmonary vein isolation procedures are the most extensively evaluated and carry the lowest stroke rate following warfarin discontinuation (0-0.4% per annum when performed as an isolated procedure). By contrast, left atrial appendage occlusion by insertion of a transcatheter device has an associated annual stroke rate of 0-3.8% off warfarin. Thus, discontinuation of warfarin following such transcatheter procedures cannot be recommended at this time. Concomitant heart surgeries, such as mitral valve repair have been shown to increase the thromboembolic rate both unpredictably and dramatically, and this review thus identifies concomitant mitral valve surgery as a potentially substantial risk factor for late thromboembolic stroke in patients undergoing corrective surgeries for atrial fibrillation. This review finds in favour of warfarin discontinuation in selected patients at three months post-procedure, emphasizing consideration of the patient's individual risk-factor profile as paramount. This recommendation is in line with the
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
Three-part question
In [patients undergoing successful surgical-or catheterbased interventions for atrial fibrillation (AF)] can [anticoagulants be discontinued postoperatively] without unacceptable risk of [thromboembolic stroke]?
Clinical scenario
A patient who is a long-time sufferer of refractory AF is referred to you. He has found warfarin thromboprophylaxis a struggle and has heard about surgical and catheter-based interventions that may be able to remove his need for indefinite oral anticoagulation. You resolve to check the literature for evidence that it is safe to discontinue oral anticoagulation following successful interventional procedures.
Search strategy
A Medline search 1948 to February 2011 was performed using the PubMed interface:
(LAA OR PVI OR Maze OR Left Atrial Appendage OR Ablation) AND (Atrial Fibrillation OR 'Atrial Fibrillation' [MeSH] ) AND (Stroke OR Thromboembolism) AND (Anticoagulation) The limits applied were that papers had to be written in English and involve human participants.
Search outcome
A total of 177 papers were found using the reported Medline search. From the search, 14 papers were selected population, and the fact that the Electrophysiol, USA, [9] hospital following LAA 3.6±1.3 years indication for LAA amputation was amputation concomitant with
The authors declare stroke prophylaxis at the time of Single-centre, various MV surgeries discontinuation of OAT as concomitant MV surgery, and not observational cohort study a significant predictor of AF; in fact only 61% of patients (level 2b)
Forty off OAT TE but fail to declare the P-value had a history of AF. Also, rhythm Sixty-seven on OAT status post surgery was not reported intention to discontinue warfarin Patients were started on three months post discharge, with warfarin, which was the actual number stopping discontinued only if their warfarin undeclared physician elected to and they had been maintained in SR for three months or more CHADS2: a scoring system for stroke risk in patients with AF. Criteria: C, congestive heart failure (1 point); H, hypertension (1 point); A, age over 75 years (1 point); D, diabetes mellitus (1 point); S, previous history of stroke or TIA (2 points).
AADs, anti-arrhythmic drugs; AF, atrial fibrillation; CFAE, complex fractionated atrial electrograms; CI, confidence interval; CPVA, circumferential pulmonary vein isolation; CrI, Bayesian credible intervals; CVA, cerebrovascular accident; ICE PVI, intracardiac electrocardiography pulmonary vein isolation; ITT, intention to treat; LAAO, left atrial appendage occlusion; LARFA, left atrial radiofrequency ablation; MV, mitral valve; OAT, oral anticoagulation; OR, odds ratio; PLAATO, percutaneous left atrial appendage transcatheter occlusion; PVA, pulmonary vein ablation; PVI, pulmonary vein isolation; SR, sinus rhythm; TE, thromboembolic event; TIA, transient ischaemic attack.
that provided evidence addressing the specific question. Selection criteria included study relevance, primary outcome, size of study population and length of follow-up. These papers are presented in Table 1 .
Results
Themistoclakis et al. [2] reported on the only large (albeit non-randomized) trial comparing warfarin discontinuation with continuation in patients following surgical correction of AF. The trial included 3355 patients who had undergone pulmonary vein isolation (PVI), and the results reported a lower rate of ischaemic stroke in the discontinuation group (P=0.06). However, selection bias resulted in the continuation group comprising the majority of patients who remained in AF, confounding the results. Nevertheless, the low absolute stroke rate in the warfarin discontinuation group (0.07% over 28±13 months) suggests that discontinuation of warfarin at three months post PVI is safe.
Smaller studies support Themistoclakis' conclusions. Pappone et al. [15] reported an annual stroke rate of 0.4% in a cohort of 589 PVI patients who discontinued warfarin three months postoperatively (provided they remained free of AF). The median follow-up was 900 days. Corrado et al. [5] reported no thromboembolic events (TEs) over a mean follow-up of 16 months in a cohort of 138 high-risk patients who stopped warfarin five to six months after undergoing PVI. Similarly, Bunch et al. [14] also recorded no strokes in a 327-day study following 123 patients undergoing irrigated catheter tip ablation who were maintained on aspirin monotherapy.
In a non-randomized retrospective study, Cox et al. [8] reported just one late stroke in 306 patients over a mean follow-up of longer than three years. All of these patients remained free of AF throughout, and the majority discontinued warfarin at three months post procedure.
Oral et al. [4] and Nademanee et al. [3] looked at patients discontinuing warfarin three months after left atrial ablation. The annual stroke rates in these studies were 0% and 0.4%, respectively. However, in Nademanee's study, patients only discontinued warfarin if they had remained free of AF throughout the immediate three postoperative months, and in fact, in those who suffered recurrence of AF and remained on warfarin, the annual stroke rate was higher, at 2%. The evidence for warfarin discontinuation following nonrhythm-correcting, left atrial appendage (LAA) occlusion strategies is less convincing. In a randomized controlled trial, Holmes et al. [10] reported the risk of ischaemic stroke off warfarin, following LAA occlusion using the WATCHMAN device (Atritech Inc, Plymouth, MN, USA.), as being just 2.2 per 100 patient-years. This was non-significantly greater than in the control arm of patients on standard warfarin therapy alone (1.6 per 100 patient-years), but was still a very low rate. This study has been criticized, however, as one-third of the patients had a CHADS2 score of only 1, and therefore were at low risk of stroke at study entry. However, Sick et al. [7] had similarly encouraging results, reporting no strokes and only two transient ischaemic attacks (TIAs) over a two-year follow-up period in 55 patients discontinuing warfarin following WATCHMAN implantation.
Multiple non-randomized studies have looked at stroke rates in patients maintained on antiplatelet therapy alone following PLAATO device LAA occlusion [6, 11, 12] . These reported a relatively low incidence of stroke of 0-3.8% per annum.
In fact, the only study found that describes a high incidence of TE in patients taken off warfarin is that reported by Almahameed et al. [9] . This study reported a 15% incidence of TE over a mean 3.6-year follow-up of just 40 patients who were taken off warfarin following concomitant LAA amputation and mitral valve surgery. However, the incidence of TE was 10% in the control arm individuals remaining on warfarin -much higher than in similar studies. Thus, it appears likely that the mitral valve itself was a major embolic source, contributing to the spuriously high TE rate in this study.
Clinical bottom line
There is a relatively large body of low-quality evidence showing warfarin discontinuation following AF surgery to be safe. The annual stroke risk following AF ablation surgery undertaken in isolation in patients in whom warfarin is discontinued is low. The current literature review puts We read with great interest the review of Gray et al. [1] concerning the safety of warfarin discontinuation after successful surgery for atrial fibrillation (AF). According to the HRS/EHRA/ECAS Expert Consensus Statement [2] , the discontinuation of warfarin therapy post ablation is not generally recommended in patients who have a CHADS2 score of =2 because of limited data regarding the safety of treatment cessation. A large body of evidence monitoring patients after curative procedures for AF, mostly after catheter ablation, highlights the fact that recurrent asymptomatic AF can occur commonly, depending on the subset of patients studied as well as the duration and frequency of monitoring. The literature suggests that although the number of undetected AF episodes may increase after catheter ablation, the duration of individual episodes decreases, usually to >24 h -a duration not associated with thromboembolic events. If warfarin is discontinued after successful ablation, it should be reinstated once AF recurrence is confirmed in high-risk patients for thromboembolic events, regardless of the type of AF. The presence of hypercoagulability in the LA of patients with paroxysmal AF and thromboembolic risk has been demonstrated, even in the non-paroxysmal period, suggesting that patients with paroxysmal AF are at high risk for developing cerebral thromboembolism even during sinus rhythm [3] . At the same time, stroke rates as well as stroke risk factors in patients with paroxysmal AF have been proven to be similar to those in patients with persistent AF [3] . Notably, advanced age and structural heart disease were independent predictors for thrombus formation in the LA. Therefore, the resumption of warfarin treatment should not be based on the type of AF, but on the thromboembolic risk in patients with AF recurrence.
AF may occur late after catheter ablation, which is not predictable by any cardiac rhythm monitoring. Late AF recurrence is more likely to occur in patients with hypertension, persistent AF, and in older patients [3] . Thus, the discontinuation of warfarin after successful ablation should be based on risk factors. However, anticoagulation therapy using warfarin involves some issues, such as bleeding, intolerability or unstable INR control, all of which may be attributable to thromboembolism in patients who are taking warfarin. The Canadian Cardiovascular Society guidelines recommend that warfarin or dabigitran be used for oral anticoagulation in patients with a CHADS2 score of =1, and concluded that dabigatran is preferred over warfarin in most the annual stroke risk at 0-0.4% in such patients, compiled from studies with a cumulative 10,000 patient-years of follow-up, where warfarin was discontinued at a mean of 3.9 months (range 0-8 months) post procedure.
However, if mitral valve surgery is performed concomitantly, stroke rates off warfarin can rise to up to 4.2% per annum, with mitral valve repair carrying a greater stroke risk than replacement. Experimental transcatheter interventional procedures that aim to occlude the LAA (namely the WATCHMAN and PLAATO devices) have a higher risk of stroke in patients off warfarin; 0-3.8% per annum has been reported from trials comprising a total of 560 patient-years of follow-up in which no warfarin was given post-procedurally. Non-randomization of studies presents a major issue when analysing the evidence, and the conclusions should be viewed in light of this. On the available evidence, we recommend cessation of anticoagulants at three months after established AF ablation procedures, but only after first considering the strokerisk profile of the individual patient. This recommendation is concordant with the European Society of Cardiology's 2010 guidelines for the management of AF [16] . doi:10.1510/icvts.2011.282319B Gray et al. provide an important evidence-based synthesis of the complex literature on atrial fibrillation and the safety of stopping anticoagulants [1] . Any evidence-based article is limited by the quality of the evidence base analysed, and their analysis raises a number of points. Firstly, the definition of' successful' needs to be made clear. Periods of paroxysmal atrial fibrillation are associated with an increased stroke rate and may need anticoagulant therapy as a prophylaxis [2] . Within the definition of successful, documentation of mechanical atrial activity and not just electrocardiogram evidence of sinus rhythm needs to be included, as an akinetic atrium has increased thomboembolic potential [3] . Secondly, the exact surgical technique of atrial fibrillation surgery needs to be stated, and concomitant surgical procedure(s) identified. The risk of a thromboembolic event will be lower in coronary artery bypass surgery patients than in mitral valve repair/replacement patients having concomitant atrial fibrillation surgery. The technique of left atrial exclusion, if indeed it was performed (sometimes omitted in elderly patients with frail tissues), may also affect thromboembolic risk. Thirdly, the patient's cardiovascular risk profile, via the CHADS2 score [4] , is an important factor, as previously ecommented on by Koniari.
patients [4] . This recommendation was based on the results of the RE-LY trial, which reported that dabigatran 150 mg po bid is superior to warfarin for the prevention of stroke with an equivalent risk of bleeding while dabigatran 110 mg po bid is equivalent to warfarin in terms of stroke prevention with a significantly reduced risk of hemorrhage [4] . Interestingly, a recent study concerning the use of dabigatran immediately after atrial fibrillation ablation revealed that there were no pre-procedural or intra-procedural thromboembolic episodes or bleeding in patients that received dabigatran. Moreover, there were no post ablation strokes, transient ischemic attacks, or systemic thromboemboli in any of the patients, rendering dabigatran a safe and well-tolerated alternative to warfarin after AF ablation [5] .
